Abstract
Monoamine oxidase (MAO) inhibitors continue to be used for treatment of a number of psychiatric and neurologic disorders. In recent years, inhibitors of MAO and other amine oxidases have received considerable attention because of their neuroprotective and neurorescue effects in such models as oxygen-glucose deprivation in vitro, thiamine deficiency, NMDA-instigated excitotoxicity, free radical-mediated oxidative stress, cerebral ischemia, and experimental models of Alzheimers and Parkinsons Diseases. This review focuses on the MAO inhibitors l-deprenyl, tranylcypromine and phenelzine and the possible mechanisms underlying their neuroprotective actions. In addition, there is a discussion of analogs of phenelzine and l-deprenyl as inhibitors of other amine oxidases, including semicarbazide-sensitive amine oxidase (SSAO), and their possible involvement in neuroprotection.
Keywords: neuroprotection, neurorescue, l-deprenyl, amine oxidase, semicarbazide-sensitive amine oxidase, phenelzine, phenylethylidenehydrazine
Current Neuropharmacology
Title: Amine Oxidase Inhibitors and Development of Neuroprotective Drugs
Volume: 2 Issue: 2
Author(s): Bernard N. Sowa, Kathryn G. Todd, A. M. I Tanay, Andrew Holt and Glen B. Baker
Affiliation:
Keywords: neuroprotection, neurorescue, l-deprenyl, amine oxidase, semicarbazide-sensitive amine oxidase, phenelzine, phenylethylidenehydrazine
Abstract: Monoamine oxidase (MAO) inhibitors continue to be used for treatment of a number of psychiatric and neurologic disorders. In recent years, inhibitors of MAO and other amine oxidases have received considerable attention because of their neuroprotective and neurorescue effects in such models as oxygen-glucose deprivation in vitro, thiamine deficiency, NMDA-instigated excitotoxicity, free radical-mediated oxidative stress, cerebral ischemia, and experimental models of Alzheimers and Parkinsons Diseases. This review focuses on the MAO inhibitors l-deprenyl, tranylcypromine and phenelzine and the possible mechanisms underlying their neuroprotective actions. In addition, there is a discussion of analogs of phenelzine and l-deprenyl as inhibitors of other amine oxidases, including semicarbazide-sensitive amine oxidase (SSAO), and their possible involvement in neuroprotection.
Export Options
About this article
Cite this article as:
Sowa N. Bernard, Todd G. Kathryn, I Tanay M. A., Holt Andrew and Baker B. Glen, Amine Oxidase Inhibitors and Development of Neuroprotective Drugs, Current Neuropharmacology 2004; 2 (2) . https://dx.doi.org/10.2174/1570159043476800
DOI https://dx.doi.org/10.2174/1570159043476800 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Postprandial Hypotension - Novel Insights into Pathophysiology and Therapeutic Implications
Current Vascular Pharmacology Chemical and Clinical Development of Darinaparsin, a Novel Organic Arsenic Derivative
Anti-Cancer Agents in Medicinal Chemistry ATP-Sensitive Potassium Channel Modulators and Cardiac Arrhythmias: An Update
Current Pharmaceutical Design Immunotherapeutic and Immunoregulatory Drugs in Haematologic Malignancies
Current Topics in Medicinal Chemistry Graphical Abstracts
Inflammation & Allergy - Drug Targets (Discontinued) Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Vicious Cycles Within the Neuropathophysiologic Mechanisms of Alzheimers Disease
Current Alzheimer Research Hypersensitivity Reactions to Last Generation Chimeric, Umanized and Human Recombinant Monoclonal Antibodies for Therapeutic Use
Current Pharmaceutical Design Herb-Drug Interactions: An Insight into Cardiovascular Diseases Based on Case Reports
Cardiovascular & Hematological Agents in Medicinal Chemistry Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain
Current Medicinal Chemistry Immunotherapy Resistance Mechanisms in Renal Cell Cancer
Current Signal Transduction Therapy Fused 1,4-Dihydropyridines as Potential Calcium Modulatory Compounds
Mini-Reviews in Medicinal Chemistry Simple and Efficient Synthesis of Novel bis-Betti Bases via a One-Pot Pseudo-Five-Component Reaction
Letters in Organic Chemistry L-Dopa Prodrugs: An Overview of Trends for Improving Parkinsons Disease Treatment
Current Pharmaceutical Design Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety
Current Pharmaceutical Design Magnetic Digital Microfluidics for Point-of-Care Testing: Where Are We Now?
Current Medicinal Chemistry Does Daily Dialysis Improve Hypertension in Chronic Haemodialysis Patients?
Current Hypertension Reviews Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology The Immune System Regulation in Sepsis: From Innate to Adaptive
Current Protein & Peptide Science